Effects of Levamisole in adjuvant immunochemotherapy for gastric cancer; a prospective randomized controlled study

The effectiveness of Levamisole combined with Mitomycin-C, FT-207 and PS-K for treating gastric cancer was investigated in a prospective randomized controlled study. All patients had undergone gastrectomy during the years from August 1977 to November 1980. Five year survival rates revealed no differ...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of surgery Vol. 13; no. 6; p. 480
Main Authors Hattori, T, Niimoto, M, Toge, T, Oride, M, Nakao, A, Yoshinaka, K
Format Journal Article
LanguageEnglish
Published Japan 01.11.1983
Subjects
Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - therapeutic use
Adult
Aged
Antibiotics, Antineoplastic - administration & dosage
Clinical Trials as Topic
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Levamisole - administration & dosage
Levamisole - therapeutic use
Male
Middle Aged
Mitomycin
Mitomycins - administration & dosage
Neoplasm Staging
Postoperative Care
Prospective Studies
Proteoglycans - administration & dosage
Random Allocation
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Online AccessGet more information

Cover

More Information
Summary:The effectiveness of Levamisole combined with Mitomycin-C, FT-207 and PS-K for treating gastric cancer was investigated in a prospective randomized controlled study. All patients had undergone gastrectomy during the years from August 1977 to November 1980. Five year survival rates revealed no difference between groups given or not given Levamisole. In those with positive lymph node metastases plus obvious serosal invasion, there was a significant elevation in the survival rate at four years after gastrectomy. The effectiveness of Levamisole was confirmed by postoperative changes in the PPD skin test, lymphocyte blastogenesis to PHA and serum inhibition index.
ISSN:0047-1909
DOI:10.1007/BF02469490